Reviews of gemcitabine, gemcitabine is a new antimetabolite, a structure similar to Ara-C.
At present, for pancreatic cancer and non-small cell lung cancer, recent clinical studies have shown that breast cancer, small cell lung cancer, also has a good effect.
Gemcitabine reviews, reports, gemcitabine ten Shun lead in the pan non-small cell lung cancer preoperatively and 1 year survival rate was 67%; in inoperable pan non-small cell lung cancer after radiotherapy applications, 1-year survival, 2 year survival rates were 63% and 47%.
Reviews of gemcitabine for advanced pancreatic cancer, although few patients to PR, but there certainly pain and improve the general effect.